The post September 14, 2026: MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo – Frontiers appeared first on ºÚÁÏÉç.

The post April 1, 2026: Third-Line Therapy Shows Limited Efficacy in Real-World aGVHD Population – Cancer Network appeared first on ºÚÁÏÉç.

The post March 23, 2026: Microbiome Therapy Achieves High ORR and Survival in Acute GI GVHD – Targeted Oncology appeared first on ºÚÁÏÉç.

The post January 29, 2026: Première thérapie standardisée en vue dans le microbiote en oncologie pour ºÚÁÏÉç – Les Echos Investir (French Only) appeared first on ºÚÁÏÉç.

The post January 26, 2026: Le Journal des biotechs : Hervé Affagard, ºÚÁÏÉç – Boursorama (French Only) appeared first on ºÚÁÏÉç.

The post December 22, 2025: Interview of Hervé Affagard – CEO and Co-Founder, ºÚÁÏÉç – Pharma Boardroom appeared first on ºÚÁÏÉç.

The post December 9, 2025: ASH 2025: ºÚÁÏÉç’s microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval – the pivotal data was presented in an oral at ASH this week – Biotech TV appeared first on ºÚÁÏÉç.

The post November 28, 2025: French Tech : Maat Pharma, un anticancer issu du microbiote – BFM Business (French Only) appeared first on ºÚÁÏÉç.

The post October 30, 2025: Éric Soyer – Directeur Financier MAAT PHARMA : Stratégie & actualités – Lyon Place Financière (French Only) appeared first on ºÚÁÏÉç.

The post September 22, 2025: Interview of Eric Soyer, CFO at ºÚÁÏÉç – Boursier.com (French Only) appeared first on ºÚÁÏÉç.